Alkemist Bio
4 known investors
ALKemist Bio develops immunotherapies targeting ALK-positive cancers, using chimeric antigen receptor (CAR) T cells and T cell receptor (TCR) engineered T cells to eliminate treatment-resistant tumors. The company focuses on oncology precision therapies for aggressive cancers including neuroblastoma and non-small cell lung cancer.